menu
    • menu

    Company profile for Amzell B.V

    NEW Drugs in Dev: 2
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Amzell BV is a specialist, virtual development pharmaceutical company which takes candidate or re purposed drugs and devices either through to proof of concept, or through to registration for sale to commercial healthcare companies. The company, which is based in Hoofddorp in the Netherlands, was founded in 2016 and is part of the Frederik Paulsen business interests which consists of a number of healthcare companies includi...
    Amzell BV is a specialist, virtual development pharmaceutical company which takes candidate or re purposed drugs and devices either through to proof of concept, or through to registration for sale to commercial healthcare companies. The company, which is based in Hoofddorp in the Netherlands, was founded in 2016 and is part of the Frederik Paulsen business interests which consists of a number of healthcare companies including Ferring Pharmaceuticals.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Amzell B.VNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Siriusdreef 41 2132WT Hoofddorp, Netherlands
    Telephone
    Telephone
    +31 23 55 60 465
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.amzell.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amzell B.V. and Amring Pharmaceuticals Inc. Attending 2021 American Epilepsy
    Amzell B.V. and Amring Pharmaceuticals Inc. Attending 2021 American Epilepsy

    02 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211202005641/en/Amzell-B.V.-and-Amring-Pharmaceuticals-Inc.-Attending-2021-American-Epilepsy-Society-Meeting-in-Chicago

    BUSINESSWIRE
    02 Dec 2021
    Share Share
    Amzell, Amring's AMZ002 Enters Phase III Trial for Infantile Epileptic Disease
    Amzell, Amring's AMZ002 Enters Phase III Trial for Infantile Epileptic Disease

    19 Nov 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211119005740/en

    BUSINESSWIRE
    19 Nov 2021
    Share Share
    Amzell,B.V., in Collaboration With Amring Pharmaceuticals Inc. Announce
    Amzell,B.V., in Collaboration With Amring Pharmaceuticals Inc. Announce

    19 Nov 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211119005740/en/Amzell-B.V.-in-Collaboration-With-Amring-Pharmaceuticals-Inc.-Announce-Their-Lead-Product-Has-Entered-Phase-III-Clinical-Trial-in-the-U.S.-for-Treatment-of-Infantile-Epileptic-Disease

    BUSINESSWIRE
    19 Nov 2021
    Share Share
    Amzell to begin phase 3 trial of AMZ002 to treat infantile epileptic disease
    Amzell to begin phase 3 trial of AMZ002 to treat infantile epileptic disease

    27 Nov 2020

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=133783&sid=2

    PHARMABIZ
    27 Nov 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search